TRANSDERM-NITRO 0.2 PATCH (EXTENDED RELEASE)

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

NITROGLYCERIN

Disponível em:

NOVARTIS PHARMACEUTICALS CANADA INC

Código ATC:

C01DA02

DCI (Denominação Comum Internacional):

GLYCERYL TRINITRATE

Dosagem:

0.2MG

Forma farmacêutica:

PATCH (EXTENDED RELEASE)

Composição:

NITROGLYCERIN 0.2MG

Via de administração:

TRANSDERMAL

Unidades em pacote:

30

Tipo de prescrição:

Ethical

Área terapêutica:

NITRATES AND NITRITES

Resumo do produto:

Active ingredient group (AIG) number: 0103615026; AHFS:

Status de autorização:

CANCELLED POST MARKET

Data de autorização:

2022-04-05

Características técnicas

_ _
_Page 1 of 34_
PRODUCT MONOGRAPH
TRANSDERM-NITRO
®
(nitroglycerin)
Transdermal Therapeutic System
Antianginal Agent
Novartis Pharmaceuticals Canada Inc.
DATE OF PREPARATION:
385 Bouchard
November 12, 1993
Dorval, Québec
H9S 1A9
DATE OF REVISION:
August 26, 2015
Control No.: 183653
TRANSDERM-NITRO is a registered trademark.
*All registered trademarks are the property of their respective
owners.
_ _
_ _
_Page 2 of 34_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................20
PHARMACEUTICAL INFORMATION
..........................................................................20
TOXICOLOGY
.................................................................................................................20
REFERENCES
...............................................